Trying To Predict the Future for People with Diabetes: A Tough but Important Task
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Editorials16 August 2005Trying To Predict the Future for People with Diabetes: A Tough but Important TaskFREEMichael M. Engelgau, MD, MSMichael M. Engelgau, MD, MSFrom the National Center for Chronic Disease Prevention and Health Promotion Centers for Disease Control and Prevention, Atlanta, GA 30341.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-143-4-200508160-00011 SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail With growing health care costs, policymakers and health care providers need information on the cost-effectiveness of interventions. This issue contains an economic evaluation (1) of a prevention policy for diabetes—a condition that affects more than 18 million persons in the United States at a cost of approximately $132 billion annually.To assist policymakers, researchers have developed models that simulate the progression of diabetes, expenditures on diabetes care, and effects of interventions. The outputs of these models include costs and health outcomes, such as length of life (often expressed as quality-adjusted life-years [QALYs]), a measure that considers the quality of life in each health state. Two principal types of diabetes models exist. Most researchers use a Markov model, which comprises disease states (for example, normal, impaired glucose tolerance [IGT], and diabetes) represented in a computer program. The computer simulates transitions from one disease state to another as chance events. A second novel type of model, named Archimedes (2, 3), uses object-oriented computer programming and complex differential equations to simulate pathophysiologic processes (for example, hepatic glucose output after a meal) that change over time and can lead to disease. For a technical explanation of the Archimedes model, I refer to the accompanying editorial in this issue (4). My editorial focuses on the clinical and policy aspects of the Archimedes model.The Archimedes model calculates the changes in costs and quality-adjusted length of life (in QALYs) from implementing the lifestyle intervention of the Diabetes Prevention Program (DPP) study (5) or prescribing metformin to a cohort with IGT like the enrollees in the DPP. Eddy and colleagues (1) took a societal perspective and used time horizons of 10, 20, and 30 years. Compared with no intervention, the cost per QALY of beginning the intensive lifestyle intervention or metformin for IGT was $62 600 and $35 400, respectively, over 30 years (1). The cost per QALY for an intensive lifestyle intervention started after the onset of diabetes was $24 500.What do these results imply for health care policy? Acceptable cost-effectiveness depends on a society's willingness to pay. Interventions that cost less than $50 000 per QALY are reasonable to consider for rapid adoption. Thus, the Archimedes model results imply that we should not rush to adopt the DPP lifestyle intervention (6).Another model, developed by the DPP Research Group (DPPRG), leads to a different conclusion. It used a Markov model, lifetime horizon, and societal perspective to determine the cost-effectiveness of the same interventions for IGT. The cost per QALY was $8800 for the lifestyle intervention and $29 900 for metformin, both less than the $50 000 threshold for rapid adoption (7). Eddy and colleagues critique the model in an online Appendix (1). Speaking as a coauthor of the DPPRG cost-effectiveness analysis, I believe that many of Eddy and colleagues' criticisms are based on inaccurate descriptions of the DPPRG model. However, my focus is to understand why the 2 models have such different policy implications.Although these 2 analyses gave different values for cost-effectiveness, several clinically relevant results were similar. First, both analyses predicted that the lifestyle intervention would substantially reduce the proportion of patients at high risk who developed diabetes. Second, both analyses predicted that the lifestyle intervention would delay the onset of diabetes. The Archimedes model predicted that the time required for 50% of patients with IGT to develop diabetes would increase from 7 years to 14 years. The corresponding figures from the DPPRG study were 8 years and 18 years, respectively. Third, both analyses predicted that the lifestyle intervention will lead to fewer complications, longer life, and improved quality of life. Fourth, both analyses suggested that the cost of the lifestyle intervention exceeds the savings from lower rates of diabetes complications.Why do the 2 studies differ in the cost per QALY of the lifestyle intervention and metformin therapy? This question is crucial because the different costs per QALY lead to different policy recommendations. To facilitate a comparison, I examined the results for the base-case cohorts (Archimedes model, no intervention; DPPRG analysis, standard lifestyle) for both models. The Archimedes' time hor
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Onset of NIDDM occurs at Least 4–7 yr Before Clinical Diagnosis
Harris, M. I., Klein, R., Welborn, T. A., & Knuiman, M. W. (1992) · Diabetes Care · doi:10.2337/diacare.15.7.815 · Cited by 1,306
Herman, W. H., Hoerger, T. J., Brandle, M., Hicks, K., Sorensen, S., Zhang, P., Hamman, R. F., Ackermann, R. T., Engelgau, M. M., Ratner, R. E., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-5-200503010-00007 · Cited by 703
Self-citationMode of onset of type 2 diabetes from normal or impaired glucose tolerance
Ferrannini, E., Nannipieri, M., Williams, K., Gonzales, C., Haffner, S. M., & Stern, M. P. (2004) · Diabetes · doi:10.2337/diabetes.53.1.160 · Cited by 153
Cited by
Diabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020
The prevention of type 2 diabetes
F. T. D. P. P. R. G., Crandall, J. P., Knowler, W. C., Kahn, S. E., Marrero, D., Florez, J. C., Bray, G. A., Haffner, S. M., Hoskin, M., & Nathan, D. M. (2008) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0843 · Cited by 261
Knowler (2011) · doi:10.1001/archinternmed.2011.367 · Cited by 194
Knowler, W. C. (2018) · Endocrinology · doi:10.1007/978-3-319-27317-4_16-1 · Cited by 194
Progression to type 2 diabetes characterized by moderate then rapid glucose increases
Mason, C. C., Hanson, R. L., & Knowler, W. C. (2007) · Diabetes · doi:10.2337/db07-0053 · Cited by 90
“For example, different economic analyses of the lifestyle intervention used in the Diabetes Prevention Program reached vastly different conclusions about its cost-effectiveness (15,16), at least partially as a consequence of different assumptions about the rate of progression of hyperglycemia (17).”
Background
Metadata
- Authors
- Engelgau, M. M.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2005-08-16
- Volume
- 143
- Issue
- 4
- Pages
- 301-302
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W1983975308
- Cited by
- 25
- References
- 4
- FWCI
- 8.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Trying To Predict the Future for People with Diabetes: A Tough but Important Task. https://app.cochat.ai/papers/10.7326/0003-4819-143-4-200508160-00011
- The paper
- Engelgau, M. M. (2005). Trying To Predict the Future for People with Diabetes: A Tough but Important Task. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-143-4-200508160-00011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.